By the 10.5-week timepoint, LNP-CTRL mice were all moribund with β-PD1 alone not impacting tumor burden, yet the combination of LNP-CTNNB1 + β-PD1 resulted in enhanced efficacy with absence of any non-responders compared to LNP-CTNNB1 + IgG treated animals (Figure 7f–g). The gene discussed is CTNNB1; the disease is neoplasm.